Terazosin Hydrochloride
Product Images NDC 53808-0305

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Terazosin Hydrochloride (NDC 53808-0305). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Terazosin HCl 1 mg Caps (Terazosin 1mg(teva))

This is a medication label for Terazosin, a prescription drug, in the form of 1mg capsules. The label indicates a quantity of 30 capsules and a lot number of Kog20. The expiration date is listed as 0B3110. The pharmacy responsible for dispensing the medication is located in Tallahassee, FL, and the medication is for oral consumption.*

FDA Label Image

Terazosin HCl 2 mg Caps (Terazosin 2mg(teva))

FDA Label Image

Chemical Structure (Terazosin Hydrochloride Capsules 1)

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

The text describes results from a study on a drug called Terazosin, showing the mean change in total symptom score and mean increase in peak flow rate from baseline for the drug compared to a placebo group. The data is presented in Figure 1 of Study 1 and indicates statistical significance with a p-value of less than 0.05. Baseline values can be found in a table mentioned in the text.*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

This is a graph showing the mean change in total symptom score from baseline over a long-term, open-label, non-placebo controlled study that included 494 participants. The graph shows the mean change over time up to 30 months in patients with a certain condition. The mean baseline score was 10.7 and the study was able to show that there was a statistically significant improvement after 7 months of treatment.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

The text describes a figure, specifically Figure 3, that represents the mean change in Peak Flow Rate from Baseline in a Long-Term, Open-Label, Non-Placebo Controlled Study. The data is presented in a graph format and shows the mean change from baseline at months 0, 1, 2, 3, 12, 15, 18, 21, 24, 27, and 30. There is a statistically significant change (p<0.05) vs. baseline, and the mean baseline is 99. The context and purpose of the study are not provided in the text.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.